---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-092017"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2026-08-06T20:13:48+00:00"
generated_at: "2026-08-06T20:18:24.972373+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics Q2 net loss $106.2M; Phase 3 ACCOMPLISH program dosed first patients

## Summary
- Net loss of $106.2M in Q2 2026 vs $61.7M in Q2 2025; R&D expenses $100.1M (up from $54.7M).
- Cash, equivalents and short-term investments $1.3B as of June 30, 2026, expected to fund operations through 2028.
- First patients dosed in Phase 3 ACCOMPLISH-1 and -2 trials of aleniglipron for chronic weight management.
- Appointed John Berrios (ex-Novo Nordisk) as Chief Commercial Officer.
- Phase 1 SAD data for ACCG-2671 and initiation of MAD trial on track for Q3 2026.

## SEC filing metadata
- accession: 0001104659-26-092017
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2026-08-06T20:13:48+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/0001104659-26-092017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/tm2622407d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-092017
- JSON: https://secwatch.observer/filing/0001104659-26-092017.json
- Plain text: https://secwatch.observer/filing/0001104659-26-092017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.